Cargando…
Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer
The purpose of this study was to evaluate quality of life (QOL) in prostate cancer patients treated with (125)I brachytherapy (BT), (125)I brachytherapy combined with 3D conformal radiation therapy (BT+3D-CRT), or intensity-modulated radiation therapy (IMRT). We evaluated disease-related QOL in pati...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430243/ https://www.ncbi.nlm.nih.gov/pubmed/30576565 http://dx.doi.org/10.1093/jrr/rry101 |
_version_ | 1783405745821188096 |
---|---|
author | Nakai, Yasushi Tanaka, Nobumichi Asakawa, Isao Anai, Satoshi Miyake, Makito Hori, Shunta Morizawa, Yosuke Tatsumi, Yoshihiro Hasegawa, Masatoshi Fujii, Tomomi Fujimoto, Kiyohide |
author_facet | Nakai, Yasushi Tanaka, Nobumichi Asakawa, Isao Anai, Satoshi Miyake, Makito Hori, Shunta Morizawa, Yosuke Tatsumi, Yoshihiro Hasegawa, Masatoshi Fujii, Tomomi Fujimoto, Kiyohide |
author_sort | Nakai, Yasushi |
collection | PubMed |
description | The purpose of this study was to evaluate quality of life (QOL) in prostate cancer patients treated with (125)I brachytherapy (BT), (125)I brachytherapy combined with 3D conformal radiation therapy (BT+3D-CRT), or intensity-modulated radiation therapy (IMRT). We evaluated disease-related QOL in patients who underwent BT, BT+3D-CRT, or IMRT, using the Expanded Prostate Cancer Index Composite questionnaire before treatment and at 3 and 24 months post-treatment. Multivariate analyses were conducted to determine factors associated with a minimum important difference (MID) in urinary, bowel, sexual, and hormone domain scores at 3 and 24 months post-treatment. Of 558 enrolled patients (IMRT, 123; BT, 230; and BT+3D-CRT, 205), urinary domain scores showed a MID after BT, BT+3D-CRT and IMRT at 3 months in 69%, 84% and 25% of patients, respectively, and at 24 months in 43%, 54% and 28% of patients, respectively. On multivariate analysis, BT+3D-CRT [3 months: odds ratio (OR) = 12.7; P < 0.001; 24 months: OR = 3.29; P = 0.001] and BT (3 months: OR = 6.28; P < 0.001 and 24 months: OR = 2.22; P = 0.027) were associated with more severely worsened urinary QOL than IMRT. Bowel domain scores showed a MID at 3 months after BT, BT+3D-CRT, and IMRT in 37%, 68% and 41% of patients, respectively, and at 24 months in 29%, 46% and 43% of patients, respectively. On multivariate analysis, BT+3D-CRT (3 months: OR = 4.20; P < 0.001 and 24 months: OR = 2.63; P < 0.001) and IMRT (24 months: OR = 1.98; P = 0.029) were associated with more severely worsened bowel QOL than was BT. Information about the changes in QOL outcomes associated with radiotherapy modalities could guide treatment decisions. |
format | Online Article Text |
id | pubmed-6430243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64302432019-03-26 Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer Nakai, Yasushi Tanaka, Nobumichi Asakawa, Isao Anai, Satoshi Miyake, Makito Hori, Shunta Morizawa, Yosuke Tatsumi, Yoshihiro Hasegawa, Masatoshi Fujii, Tomomi Fujimoto, Kiyohide J Radiat Res Regular Paper The purpose of this study was to evaluate quality of life (QOL) in prostate cancer patients treated with (125)I brachytherapy (BT), (125)I brachytherapy combined with 3D conformal radiation therapy (BT+3D-CRT), or intensity-modulated radiation therapy (IMRT). We evaluated disease-related QOL in patients who underwent BT, BT+3D-CRT, or IMRT, using the Expanded Prostate Cancer Index Composite questionnaire before treatment and at 3 and 24 months post-treatment. Multivariate analyses were conducted to determine factors associated with a minimum important difference (MID) in urinary, bowel, sexual, and hormone domain scores at 3 and 24 months post-treatment. Of 558 enrolled patients (IMRT, 123; BT, 230; and BT+3D-CRT, 205), urinary domain scores showed a MID after BT, BT+3D-CRT and IMRT at 3 months in 69%, 84% and 25% of patients, respectively, and at 24 months in 43%, 54% and 28% of patients, respectively. On multivariate analysis, BT+3D-CRT [3 months: odds ratio (OR) = 12.7; P < 0.001; 24 months: OR = 3.29; P = 0.001] and BT (3 months: OR = 6.28; P < 0.001 and 24 months: OR = 2.22; P = 0.027) were associated with more severely worsened urinary QOL than IMRT. Bowel domain scores showed a MID at 3 months after BT, BT+3D-CRT, and IMRT in 37%, 68% and 41% of patients, respectively, and at 24 months in 29%, 46% and 43% of patients, respectively. On multivariate analysis, BT+3D-CRT (3 months: OR = 4.20; P < 0.001 and 24 months: OR = 2.63; P < 0.001) and IMRT (24 months: OR = 1.98; P = 0.029) were associated with more severely worsened bowel QOL than was BT. Information about the changes in QOL outcomes associated with radiotherapy modalities could guide treatment decisions. Oxford University Press 2019-03 2018-12-20 /pmc/articles/PMC6430243/ /pubmed/30576565 http://dx.doi.org/10.1093/jrr/rry101 Text en © © The Author(s) 2018. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited |
spellingShingle | Regular Paper Nakai, Yasushi Tanaka, Nobumichi Asakawa, Isao Anai, Satoshi Miyake, Makito Hori, Shunta Morizawa, Yosuke Tatsumi, Yoshihiro Hasegawa, Masatoshi Fujii, Tomomi Fujimoto, Kiyohide Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer |
title | Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer |
title_full | Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer |
title_fullStr | Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer |
title_full_unstemmed | Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer |
title_short | Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer |
title_sort | quality of life in patients who underwent (125)i brachytherapy, (125)i brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer |
topic | Regular Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430243/ https://www.ncbi.nlm.nih.gov/pubmed/30576565 http://dx.doi.org/10.1093/jrr/rry101 |
work_keys_str_mv | AT nakaiyasushi qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT tanakanobumichi qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT asakawaisao qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT anaisatoshi qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT miyakemakito qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT horishunta qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT morizawayosuke qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT tatsumiyoshihiro qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT hasegawamasatoshi qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT fujiitomomi qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer AT fujimotokiyohide qualityoflifeinpatientswhounderwent125ibrachytherapy125ibrachytherapycombinedwiththreedimensionalconformalradiationtherapyorintensitymodulatedradiationtherapyforprostatecancer |